Cocrystal Pharma, HitGen and InterX Enter into Drug Discovery Collaboration

Cocrystal Pharma (OTCQB:COCP) entered into a research collaboration with HitGen and InterX to develop small molecule drug candidates against undisclosed targets.
As quoted in the press release:

Through the collaboration, Cocrystal, HitGen and InterX scientists will apply HitGen’s DNA-encoded library (DEL) technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs. The DEL technology enables a large number of compounds to be rapidly identified for specific drug targets. Cocrystal will use its industrialized crystallization and co-crystallization technology to determine at near atomic resolution the structures of HitGen’s selected library compounds that interact with drug targets. Finally, InterX will use its advanced proprietary software to design superior drugs from the information provided by Cocrystal and HitGen.
The goal of the collaboration is to produce superior drugs rapidly, without the need for extensive time-consuming and expensive chemical synthesis and testing. A Joint Steering Committee will oversee the project and manage the program. InterX software combined with the structural information from Cocrystal can predict the strength of drug-target interactions using the most advanced computer algorithms available today.

Click here to read the full press release.

Source: www.marketwired.com